Skip to content
Open access

HRS-7249, a small interfering RNA targeting apolipoprotein C3, in healthy subjects

Oct 2026 · European Heart Journal · 0 citations

Abstract

Apolipoprotein C3 (APOC3) is involved in the metabolism of triglyceride (TG) and is a novel target for the treatment of hypertriglyceridemia. HRS-7249 is a small interfering RNA designed to disrupt and inhibit the expression of APOC3 and consequently lower TG level. This phase 1 study aimed to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-7249 in healthy subjects. In this randomized, double-blind, placebo-controlled single ascending dose study, 6 dose cohorts were planned (10, 50, 100, 200, 400, and 600 mg). Each cohort planned to enroll 8 healthy subjects, randomized in a 6:2 ratio to receive subcutaneous HRS-7249 or placebo. The primary endpoint was safety and tolerability. 48 subjects were enrolled and treated (HRS-7249, n = 36; placebo, n = 12). Treatment-emergent adverse events (AE) were reported by 34 (94.4%) subjects in the HRS-7249 group and 8 (66.7%) subjects in the placebo group, most of which were mild in severity. The most common AE related to HRS-7249 was increased alanine aminotransferase (19.4%). Serum APOC3 concentrations considerably decreased following HRS-7249 treatment, while that in the placebo group fluctuated around the baseline (Figure). APOC3 in the HRS-7249 group decreased in a roughly dose-dependent manner across 10 to 600 mg, with the largest mean percent change ranging from -71.3% to -97.0%. TG reduction showed similar trends, ranging from -62.2% to -74.7%. HRS-7249 showed acceptable safety and tolerability and can effectively lower APOC3 and TG in healthy subjects.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.